Markets
Alignment with Large and Dynamic Segments of Cancer Diagnostics
Market Segment
Prostate Cancer Diagnostics
Scope includes preliminary and confirmatory testing, ultra sound based diagnostics as well as molecular diagnostics
2024: $4.1Bn ¹
CAGR: 13% ¹
Oncology Companion Diagnostics
Scope includes Immunohistochemistry and next-generation sequencing, multiple
cancer type
2024: $3.2Bn ¹
CAGR: 13% ¹
Oncology Molecular Diagnostics
Scope includes instruments and reagents, multiple cancer and molecule type
2024: $3.7Bn ²
CAGR: 13% ²
2024
$4.1Bn ¹
$3.2Bn ¹
$3.7Bn ²
CAGR
13% ¹
13% ¹
13% ²
Main Drivers
Increasing prevalence of cancers due to the growing geriatric population and changing lifestyles
Progress in cancer detection and patient awareness
Technological advancements in imaging, sequencing
Drug and diagnostics co-development models
Personalized Medicine
Government initiatives
Large Current and Growing Market
Number of patients that die annually of prostate cancer is 250,000/yr in USA (437,000/yr Including EU/UK market)
Number of patients with cancer relevant to the company is 870,000/yr in USA (1,455,000 /yr including EU/UK market)
(1) Grand View Research
(2) IMARC
100 East Lancaster Ave
Room R234
Wynnewood, Pennsylvania 19096
General inquiries:
© 2025 StromaGenesis. All rights reserved.
Privacy Policy